BioMarin will also assume approximately $15 million dollars in liabilities of Medicis, which represents payments owed by Medicis to the original developers of Orapred. BioMarin has entered into a Transition Services Agreement with Medicis in which Medicis will provide support services to BioMarin for up to three months following the close.
"Our line-up of products that we expect could be commercialized by the new field force, assuming favorable clinical data and FDA approval, include an additional Orapred product in the second half of 2005, Aryplase for MPS VI, late next year or early in 2006, another Orapred product in late 2006 or early in 2007, Phenoptin for mild to moderate PKU in 2007, and Phenylase for severe PKU in 2008 or 2009.
Price continued, "We believe that there is significant growth potential in the Orapred family of products from increasing penetration of the current product with additional pediatricians not called on presently, expanding usage with called on pediatricians arising from Orapred's benefits in aiding compliance, the continuing growth in the number of asthma patients, the introduction of two new proprietary Orapred products that will be aimed also to older children, and the introduction of Orapred into markets outside of the United States.
has launched a generic version of BioMarin's Orapred
. Under the authorized generics agreement BioMarin is manufacturing a private label version of the oral solution (prednisolone sodium phosphate EQ 15-mg base/5 ml), which is being marketed by Hi-Tech.
Primsol solution, an antibiotic for acute otitis media, and Orapred
, an asthma treatment in an improved-tasting formulation of liquid prenisolone sodium phosphate, could be launched in the second half of this year pending approval by the Food and Drug Administration.